Overview

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Status:
Not yet recruiting

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine if axicabtagene ciloleucel is superior to standard of care therapy (SOCT), as measured by progression-free survival (PFS) in participants with relapsed/refractory follicular lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Bendamustine Hydrochloride
Cyclophosphamide
Doxorubicin
Fludarabine
Lenalidomide
Prednisone
Rituximab
Vincristine